A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
for ER+ HER2- Advanced Breast Cancer
4 locations incl. St Louis
Sponsor: AstraZeneca
Sex: Female·Age: 18+
Code: NCT06188520·Phase 1, Phase 2·Recruiting